GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization
Patients with diabetes and cancer who received GLP-1 RA experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin. Additionally, patients already on metformin and newly started on GLP-1 RA demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the benefits of GLP-1 RA in patients with diabetes and cancer.
Authors
- Zoe Quandt (ORCID: https://orcid.org/0000-0002-4568-4368)
- Aidan Vosooghi (ORCID: https://orcid.org/0000-0003-0558-0190)
- Katy K. Tsai
- Ruthvik Sunil Kumar
- Aditya Mahadevan
- Jagmeet S Arora
- Gagandeep Singh
Institutions
- University of Kentucky (US)
- University of California, San Francisco (US)
- University of California, Irvine (US)
- University of Michigan (US)
- Michigan Medicine (US)
- Irvine University (US)
- University of California, Davis (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1210/clinem/dgaf703
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59